title: Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma.
abstract: It is known that the topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of lymphoma. Five patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) were treated with a combination of oral MST-16 and VP-16 over a long period. Two patients had severely refractory NHL. The remaining 3 patients could not be treated with intensive chemotherapy because of severe organ dysfunction or a poor hematopoietic reserve. All 5 are alive and well after MST-16 and VP-16 treatment. MST-16 and VP-16 are effective for NHL when intensive chemotherapy is ineffective or contraindicated.
authors.affiliation: Second Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. tak-o@hyo-med.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: A
authors.initials: A
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Saheki
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Takatsuka
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: A
authors.initials: A
authors.lastname: Tamura
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimori
authors.forename: E
authors.initials: E
authors.lastname: Kakishita
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000201:enzymology; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000201:enzymology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000201:enzymology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000201:enzymology; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D059005:Topoisomerase II Inhibitors
chemical_list: D010879:Piperazines; D059005:Topoisomerase II Inhibitors; D005047:Etoposide; C057773:sobuzoxane